Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors

Open access
Ellison, David W., Aldape, Kenneth D., Capper, David, Fouladi, Maryam, Gilbert, Mark R., Gilbertson, Richard J., Hawkins, Cynthia, Merchant, Thomas E., Pajtler, Kristian, Venneti, Sriram, Louis, David N. · 2020 · Brain Pathology

Abstract

Advances in our understanding of the biological basis and molecular characteristics of ependymal tumors since the latest iteration of the World Health Organization (WHO) classification of CNS tumors (2016) have prompted the cIMPACT‐NOW group to recommend a new classification. Separation of ependymal tumors by anatomic site is an important principle of the new classification and was prompted by methylome profiling data to indicate that molecular groups of ependymal tumors in the posterior fossa and supratentorial and spinal compartments are distinct. Common recurrent genetic or epigenetic alterations found in tumors belonging to the main molecular groups have been used to define tumor types at intracranial sites; C11orf95 and YAP1 fusion genes for supratentorial tumors and two types of posterior fossa ependymoma defined by methylation group, PFA and PFB. A recently described type of aggressive spinal ependymoma with MYCN amplification has also been included. Myxopapillary ependymoma and subependymoma have been retained as histopathologically defined tumor types, but the classification has dropped the distinction between classic and anaplastic ependymoma. While the cIMPACT‐NOW group considered that data to inform assignment of grade to molecularly defined ependymomas are insufficiently mature, it recommends assigning WHO grade 2 to myxopapillary ependymoma and allows grade 2 or grade 3 to be assigned to ependymomas not defined by molecular status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bpa.12866

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 278

Metadata

Authors
Ellison, D. W., Aldape, K. D., Capper, D., Fouladi, M., Gilbert, M. R., Gilbertson, R. J., Hawkins, C., Merchant, T. E., Pajtler, K., Venneti, S., & Louis, D. N.
Venue
Brain Pathology
Publisher
Wiley
Published
2020-06-23
Volume
30
Issue
5
Pages
863-866
ISSN
  • 1015-6305 (ISSN-L)
  • 1750-3639
OpenAlex
W3034140733
Cited by
278
References
20
FWCI
20.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors. https://app.cochat.ai/papers/10.1111/bpa.12866
The paper
Ellison, D. W., Aldape, K. D., Capper, D., Fouladi, M., Gilbert, M. R., Gilbertson, R. J., Hawkins, C., Merchant, T. E., Pajtler, K., Venneti, S., & Louis, D. N. (2020). cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology. https://doi.org/10.1111/bpa.12866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.